高同型半胱氨酸血症对阿替普酶静脉溶栓治疗急性缺血性脑卒中疗效的影响

被引：18

作者：

姚伯昕 ^{[1
]}

黄银辉 ^{[2
]}

陈雅芳 ^{[1
]}

欧阳宛炯 ^{[1
]}

蔡若蔚 ^{[1
]}

机构：

[1] 福建医科大学附属第二医院神经内科

[2] 福建省晋江市医院神经内科

来源：

第三军医大学学报 | 2014年 / 36卷 / 19期

关键词：

高同型半胱氨酸; 组织型纤溶酶原激活物; 缺血性脑卒中; 预后;

D O I：

10.16016/j.1000-5404.2014.19.022

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

摘要：

目的探讨高同型半胱氨酸血症对急性缺血性脑卒中患者静脉溶栓疗效的影响。方法连续收集符合阿替普酶静脉溶栓治疗条件的162例急性缺血性脑卒中患者作为研究对象。根据90 d时改良Rankin量表评分(mRS评分),将患者分为预后良好组(mRS评分0～1分)和预后不良组(mRS评分2～6分),用单因素分析及多因素回归分析对两组患者危险因素进行比较。结果根据mRS评分,90 d时预后良好88例。90 d预后不良74例。预后良好组患者的年龄、溶栓前NIHSS评分、血糖、INR及溶栓后2 h收缩压、24 h收缩压低于预后不良组(P<0.05,P<0.01),糖尿病与高同型半胱氨酸血症的比例低于预后不良组(P<0.01),两组在其他方面差异无统计学意义(P>0.05)。Logistic分析显示糖尿病、溶栓前血糖、溶栓前NIHSS评分、溶栓后2 h收缩压、溶栓后24 h收缩压、高同型半胱氨酸血症均是溶栓预后独立的影响因素。结论高同型半胱氨酸血症会影响缺血性脑卒中患者的溶栓预后。

引用

页码：2044 / 2047

页数：4

共 12 条

[1] Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. Wang Xiaoying,Rosell Anna,Lo Eng H. CNS & neurological disorders drug targets . 2008
[2] Annexin II: a plasminogen-plasminogen activator co-receptor. Kim Jiyun,Hajjar Katherine A. Frontiers in bioscience : a journal and virtual library . 2002
[3] An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. Hajjar K A,Jacovina A T,Chacko J. Journal of Biological Chemistry . 1994
[4] Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. Hacke Werner,Kaste Markku,Bluhmki Erich,Brozman Miroslav,Dávalos Antoni,Guidetti Donata,Larrue Vincent,Lees Kennedy R,Medeghri Zakaria,Machnig Thomas,Schneider Dietmar,von Kummer Rüdiger,Wahlgren Nils,Toni Danilo. The New England Quarterly . 2008
[5] Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator. Huang YH,Zhuo ST,Chen YF,et al. Chinese Medical Journal . 2013
[6] Atherosclerosis, serum cholesterol and the homocysteine theory: a study of 194 consecutive autopsies. McCully K S. The American journal of the medical sciences . 1990
[7] Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Clarke R.,Halsey J.,Lewington S.,Armitage J.,Bennett D.,Peto R.,Collins R.,Lonn E.,Manson J.E.,Gaziano J.M.,Bonaa K.H.,Spence J.D.,Nygard O.,Jamison R.,Guarino P.,Mir F. Archives of Internal Medicine . 2010
[8] Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B12[!/sub] vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors : A Randomized Trial. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Grou. The Journal of The American Medical Association . 2010
[9] Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. David S Wald,Malcolm Law,Joan K Morris. British Medical Journal . 2002
[10] Relation of homocysteine levels with patency and flow rate of infarct related artery in patients receiving fibrinolytic therapy. Telat Keles,Ekrem Yeter,Tahir Durmaz. ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY . 2010

← 1 2 →